A
Andrew Zhang
Researcher at Yale University
Publications - 16
Citations - 488
Andrew Zhang is an academic researcher from Yale University. The author has contributed to research in topics: Chemistry & Biology. The author has an hindex of 6, co-authored 11 publications receiving 409 citations.
Papers
More filters
Journal ArticleDOI
A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules.
Andrew Zhang,Ryan P. Murelli,Cyril Barinka,Julien Michel,Alexandra Cocleaza,William L. Jorgensen,Jacek Lubkowski,David Spiegel +7 more
TL;DR: In-depth biochemical, crystallographic, and computational investigations reveal a previously unreported arene-binding site on PSMA, which is believed to participate in an aromatic stacking interaction with ARMs, which provides critical insights into the design of PSMA-targeted small molecules.
Journal ArticleDOI
Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.
TL;DR: A thorough discussion of contributions in synthetic immunology, beginning with the history of small-molecule-based technologies for modulating antibody recognition, followed by a systematic review of the various applications of ARM-based strategies.
Journal ArticleDOI
Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.
TL;DR: The design, synthesis, and biological evaluation of a class of bifunctional small molecules called antibody-recruiting molecules targeting prostate cancer (ARM-Ps) that enhance the recognition of prostate cancer cells by the human immune system are reported.
Journal ArticleDOI
Chemically Synthesized Molecules with the Targeting and Effector Functions of Antibodies
Patrick J. McEnaney,Kelly J. Fitzgerald,Andrew Zhang,Eugene F. Douglass,Weifang Shan,Aaron Balog,Mariya D. Kolesnikova,David Spiegel +7 more
TL;DR: A novel class of molecules of intermediate size, which possess both the targeting and effector functions of antibodies, which bind simultaneously to prostate-specific membrane antigen and Fc gamma receptor I, thus eliciting highly selective cancer cell phagocytosis are reported.
Journal ArticleDOI
Limitations and niches of the active targeting approach for nanoparticle drug delivery
TL;DR: The active targeting approach is best suited for delivering membrane impermeable drugs to targets directly exposed to i.v. injected nanoparticles, such as those in circulation or in the luminal site of tumor vasculatures.